Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3

Drug Metabolism and Disposition

Volumn 42, Issue 12, 2014, Pages 2041-2048

  Chioukh, Rym ^a,c   Noel Hudson, Marie Sophie ^a,c   Ribes, Sandy ^a,c   Fournier, Natalie ^b,c   Becquemont, Laurent ^a,c,d   Verstuyft, Celine ^a,c,d  

^a EA4123   (France)

^b EA 4529   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ESTRONE SULFATE; LANSOPRAZOLE; METHOTREXATE; OMEPRAZOLE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PANTOPRAZOLE; ESTRONE; ORGANIC ANION TRANSPORTER; PROTON PUMP INHIBITOR;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG INTERACTION; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EXCRETION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; CELL LINE; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CELL LINE; DRUG INTERACTIONS; ESTRONE; HEK293 CELLS; HUMANS; KIDNEY TUBULES, PROXIMAL; METHOTREXATE; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-AMINOHIPPURIC ACID; PROTON PUMP INHIBITORS;

EID: 84910072268     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058529     Document Type: Article

References (52)

1. Aherne GW, Piall E, Marks V, Mould G, and White WF (1978) Prolongation and enhancement of serum methotrexate concentrations by probenecid. BMJ 1:1097-1099.
2. Bauters TG, Verlooy J, Robays H, and Laureys G (2008) Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci 30:316-318.
3. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesúmega L, and Giráldez J (2000) Potential interaction between methotrexate and omeprazole. Ann Pharmacother 34:1024-1027.
4. Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, and Schellens JH (2004) Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64:5804-5811.
5. Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, Palm JE, Stieger B, and Evers R; International Transporter Consortium (2013) In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther 94:95-112.
6. Burckhardt BC and Burckhardt G (2003) Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 146:95-158.
7. Burckhardt G (2012) Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 136:106-130.
8. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, and Endou H (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277-1286.
9. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144-3150.
10. El-Sheikh AA, Greupink R, Wortelboer HM, van den Heuvel JJ, Schreurs M, Koenderink JB, Masereeuw R, and Russel FG (2013) Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4. Transl Res 162:398-409.
11. Freston JW, Chiu YL, Mulford DJ, and Ballard D, 2nd (2003) Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 17:361-367.
12. Giacomini KM and Huang SM (2013) Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther 94:3-9.
13. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
14. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
15. Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, and Zhang L; International Transporter Consortium (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther 94:52-63.
16. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, and Hasegawa J, et al. (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485-492.
17. Ishizaki T and Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 (Suppl 3):27-36.
18. Ito K, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, and Cole SP (2001) Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem 276:38108-38114.
19. Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, and Beijnen JH (2006) Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 62:71-80.
20. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, and Chabner BA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094-1104.
21. Kurata T, Iwamoto T, Kawahara Y, and Okuda M (2014) Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3. Drug Metab Pharmacokinet 29: 148-153.
22. Launay-Vacher V, Izzedine H, Karie S, Hulot JS, Baumelou A, and Deray G (2006) Renal tubular drug transporters. Nephron Physiol 103:97-106.
23. Levêque D, Santucci R, Gourieux B, and Herbrecht R (2011) Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev Clin Pharmacol 4:743-750.
24. Lu R, Chan BS, and Schuster VL (1999) Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol 276:F295-F303.
25. Maeda A, Tsuruoka S, Kanai Y, Endou H, Saito K, Miyamoto E, and Fujimura A (2008) Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur J Pharmacol 596:166-172.
26. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, and Schwab M (2011) Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS ONE 6: e22163.
27. Nozaki Y, Kusuhara H, Endou H, and Sugiyama Y (2004) Quantitative evaluation of the drugdrug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther 309:226-234.
28. Nozaki Y, Kusuhara H, Kondo T, IwakiM, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, and Sugiyama Y (2007) Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322:1162-1170.
29. Pue MA, Laroche J, Meineke I, and de Mey C (1993) Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 44:575-578.
30. Regårdh CG, Andersson T, Lagerström PO, Lundborg P, and Skånberg I (1990) The pharmacokinetics of omeprazole in humans-a study of single intravenous and oral doses. Ther Drug Monit 12:163-172.
31. Reid T, Yuen A, Catolico M, and Carlson RW (1993) Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 33:82-84.
32. Rizwan AN and Burckhardt G (2007) Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450-470.
33. Santucci R, Levêque D, Lescoute A, Kemmel V, and Herbrecht R (2010) Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res 30: 3807-3810.
34. Shen DD and Azarnoff DL (1978) Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 3:1-13.
35. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, and Drouet E, et al. (2011) Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-STElevation Myocardial Infarction (FAST-MI) registry. Circulation 123:474-482.
36. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, and Kohda Y (2009) Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67:44-49.
37. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, and Endou H (2002a) Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 302:666-671.
38. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, and Endou H (2002b) Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300:918-924.
39. Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H, and Meyer FP (2002) Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ 324:1497.
40. Tugwell P, Bennett K, and Gent M (1987) Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 107:358-366.
41. Uwai Y, Ida H, Tsuji Y, Katsura T, and Inui K (2007) Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 24:811-815.
42. Uwai Y and Iwamoto K (2010) Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet 25: 163-169.
43. Uwai Y, Okuda M, Takami K, Hashimoto Y, and Inui K (1998) Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett 438:321-324.
44. Uwai Y, Taniguchi R, Motohashi H, Saito H, Okuda M, and Inui K (2004) Methotrexateloxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet 19:369-374.
45. Vakily M, Amer F, Kukulka MJ, and Andhivarothai N (2005) Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol 45:1179-1186.
46. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, and Nigam SK (2008) Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol 294:F867-F873.
47. Vanwert AL, Srimaroeng C, and Sweet DH (2008) Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol 74:122-131.
48. VanWert AL and Sweet DH (2008) Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates. Pharm Res 25: 453-462.
49. Whelan J, Hoare D, and Leonard P (1999) Omeprazole does not alter plasma methotrexate clearance. Cancer Chemother Pharmacol 44:88-89.
50. Widemann BC and Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694-703.
51. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, and Ishizaki T (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 49-hydroxylation status. Clin Pharmacol Ther 58:143-154.
52. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, and Nagar S, et al.; International Transporter Consortium (2013) ITC recommendations for transporter kinetic parameter estimation and translational modeling of transportmediated PK and DDIs in humans. Clin Pharmacol Ther 94:64-79.